Biotech Stocks

Novo struggles to appease restive investors with consumer plans, blockbuster ambitions

FiercePharma 4h ago

With reports leaking out of investor discontent, CEO Mike Doustdar opened Novo's Capital Markets Day by acknowledging that the company’s leadership “have to convince” the audience that “there is a bright future for Novo.”

Discussion

Sign in to join the discussion. Comments loading…